PEAK6 Investments’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-93,500
Closed -$65K 5891
2020
Q4
$65K Buy
+93,500
New +$199K ﹤0.01% 4160
2020
Q3
Sell
-93,500
Closed -$335K 5142
2020
Q2
$335K Buy
+93,500
New +$337K ﹤0.01% 3008

Other funds holding BMY.RT

PEAK6 Investments's BMY.RT Position: Q1 2021 in Review

PEAK6 Investments sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 8,160 shares — an estimated $6K sold.

PEAK6 Investments first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $5.68M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • PEAK6 Investments reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • PEAK6 Investments sold 8,160 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $6K.
  • PEAK6 Investments first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • PEAK6 Investments's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $5.68M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on PEAK6 Investments's 13F filing for Q1 2021, filed 14 May 2021.